William Rhodes and Louise Tilzer-Rhodes Center for Glioblastoma at New York Presbyterian Hospital
Glioblastoma is the most common form of malignant brain tumor and is known for its rapid growth and resistance to most treatments. Only one in 10 glioblastoma patients survive five years after initial diagnosis. Despite some treatment advances in recent years, malignant brain tumors on the whole are the most common cause of cancer-related deaths among adolescents and young adults ages 15-39.
The William Rhodes and Louise Tilzer-Rhodes Center for Glioblastoma at NewYork-Presbyterian aims to advance care for glioblastoma and other brain cancers via a three-pronged approach: providing multidisciplinary, research-driven patient care, with a focus on genomic and precision medicine; emphasizing translational research to rapidly bring promising new therapies from the bench to the bedside; and educating the next generation of clinicians and scientists, with new fellowships created to expose young physicians to the most cutting-edge work being done in the field.
NewYork-Presbyterian has established the William Rhodes and Louise Tilzer-Rhodes Center for Glioblastoma. The new state-of-the-art program conducts groundbreaking research and provides cutting-edge treatments for glioblastoma and other deadly brain cancers.
The Center is led by physicians from Columbia University Medical Center and Weill Cornell Medicine, who, along with NewYork-Presbyterian, are national leaders in neuro-oncology. William Rhodes has been a trustee, and now a life trustee of the NewYork-Presbyterian since 1992, is also issuing a challenge grant program to accelerate fundraising for the new center.
Louise Tilzer Center:https://www.nyp.org/neuro/serv
Glioblastoma is the most common form of malignant brain tumor and is known for its rapid growth and resistance to most treatments. Only one in 10 glioblastoma patients survive five years after initial diagnosis. Despite some treatment advances in recent years, malignant brain tumors on the whole are the most common cause of cancer-related deaths among adolescents and young adults ages 15-39.
The William Rhodes and Louise Tilzer-Rhodes Center for Glioblastoma at NewYork-Presbyterian aims to advance care for glioblastoma and other brain cancers via a three-pronged approach: providing multidisciplinary, research-driven patient care, with a focus on genomic and precision medicine; emphasizing translational research to rapidly bring promising new therapies from the bench to the bedside; and educating the next generation of clinicians and scientists, with new fellowships created to expose young physicians to the most cutting-edge work being done in the field.
NewYork-Presbyterian has established the William Rhodes and Louise Tilzer-Rhodes Center for Glioblastoma. The new state-of-the-art program conducts groundbreaking research and provides cutting-edge treatments for glioblastoma and other deadly brain cancers.
The Center is led by physicians from Columbia University Medical Center and Weill Cornell Medicine, who, along with NewYork-Presbyterian, are national leaders in neuro-oncology. William Rhodes has been a trustee, and now a life trustee of the NewYork-Presbyterian since 1992, is also issuing a challenge grant program to accelerate fundraising for the new center.
Louise Tilzer Center:https://www.nyp.org/neuro/serv